Physician profile
Arthur E Benzick
NPI 1376500843
$2,976.72
in general payments reported to CMS, 2019-2025
30 companies · $581 in 2025
The $581 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $63.75 · 2021: $313 · 2022: $314 · 2023: $611 · 2024: $950 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $1,045.12 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $430.23 | 2019-2024 | Arexvy, Shingrix, Bexsero |
| Merck Sharp & Dohme LLC | $215.80 | 2021-2025 | Gardasil 9, Vaxelis, Proquad |
| Sanofi Pasteur INC. | $171.30 | 2019-2025 | |
| Cranial Technologies, INC | $149.16 | 2019-2025 | Doc Band |
| Tris Pharma INC | $122.11 | 2023 | Dyanavel Xr, Quillivant, Quillichew Er |
| Ars Pharmaceuticals Operations, INC. | $121.84 | 2025 | Neffy |
| Pfizer INC. | $120.52 | 2022-2025 | |
| Genentech USA, INC. | $63.16 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $61.57 | 2021 | |
| Novo Nordisk INC | $59.97 | 2023-2025 | Rybelsus, Ozempic |
| Kaleo, INC. | $42.65 | 2022 | |
| Dynavax Technologies Corporation | $32.76 | 2022-2024 | Heplisav-B |
| Dexcom, INC. | $31.12 | 2022-2023 | Dexcom G6 Transmitter |
| Seqirus USA INC | $30.08 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $29.04 | 2025 | Azstarys |
| Acella Pharmaceuticals, LLC | $26.06 | 2023 | NP Thyroid 60 |
| Sanofi-Aventis U.S. LLC | $22.40 | 2025 | |
| Xeris Pharmaceuticals, INC. | $22.39 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.77 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.86 | 2022 | |
| Esperion Therapeutics, INC. | $17.84 | 2021 | |
| Alk-Abello, INC | $16.68 | 2025 | Neffy, Grastek, Odactra |
| Ironshore Pharmaceuticals INC. | $16.66 | 2019 | |
| Antares Pharma, INC. | $15.98 | 2021 | |
| Neos Therapeutics, LP | $15.41 | 2019 | |
| Lilly USA, LLC | $15.19 | 2023 | Jardiance |
| Inspire Medical Systems, INC. | $13.95 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $13.55 | 2022 | |
| Amarin Pharma, INC. | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Benzick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.